UBAP2L and hepatocellular carcinoma: UBAP2L has been reported to be highly expressed in multiple cancers, and knockdown of UBAP2L could suppress malignant behaviors in cancer cells, including breast cancer, hepatocellular carcinoma, and prostate cancer [13–15].